IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc., the developer of the first rechargeable Sacral Neuromodulation (r-SNM™) System for the treatment of urinary and fecal ...

The race to treat a number of health conditions using neurostimulation technology is a marathon, not a sprint—but Medtronic and Axonics Modulation Technologies are still aiming for a photo finish. For ...

Axonics Modulation Technologies Inc. Chief Executive Ray Cohen is nothing if not confident about becoming the market leader in his urology device category, despite renewed competition from medtech ...

Boston Scientific added SNM to its urology portfolio following its 2024 acquisition of Axonics.

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that ...

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our ...

Axonics Modulation Technologies (AXNX) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.54 per share a year ago.

* AXONICS MODULATION TECHNOLOGIES INC - MOST EMPLOYEES WILL BE TAKING TEMPORARY 20% CUT IN BASE SALARY FOR REMAINDER OF Q2 2020 DUE TO COVID-19 IMPACT Sign up here. * AXONICS MODULATION TECHNOLOGIES - ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Axonics Modulation Technologies (AXNX) reports results for the quarter ended December 2019. While this widely-known ...

Morgan Stanley has decided to maintain its Overweight rating of Axonics (NASDAQ:AXNX) and raise its price target from $73.00 to $80.00. Shares of Axonics are trading up 5.7% over the last 24 hours, at ...